YU29099A - Derivati 2-(purin-9-il)-tetrahidrofuran-3,4-diola - Google Patents

Derivati 2-(purin-9-il)-tetrahidrofuran-3,4-diola

Info

Publication number
YU29099A
YU29099A YU29099A YU29099A YU29099A YU 29099 A YU29099 A YU 29099A YU 29099 A YU29099 A YU 29099A YU 29099 A YU29099 A YU 29099A YU 29099 A YU29099 A YU 29099A
Authority
YU
Yugoslavia
Prior art keywords
purin
tetrahydrofuran
diol derivatives
diol
derivatives
Prior art date
Application number
YU29099A
Other languages
English (en)
Inventor
Brian Cox
David George Allen
Michael David Barker
Suzanne Elaine Keeling
Joanna Victoria Geden
Heather Hobbs
Alison Judith Redgrave
Thomas Davis Roper
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626846.1A external-priority patent/GB9626846D0/en
Priority claimed from GBGB9626852.9A external-priority patent/GB9626852D0/en
Priority claimed from GBGB9626845.3A external-priority patent/GB9626845D0/en
Priority claimed from GBGB9720536.3A external-priority patent/GB9720536D0/en
Priority claimed from GBGB9722730.0A external-priority patent/GB9722730D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of YU29099A publication Critical patent/YU29099A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

U ovom pronalasku daju se nova jedinjenja formule (I) u kojoj su R1, R2 i R3 opisani u specifikaciji, postupci njihovog dobijanja, formulacije koje ih sadrže i njihova upotreba u lečenju zapaljivih bolesti.[There are provided according to the invention novel compounds of formula (I) wherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
YU29099A 1996-12-24 1997-12-22 Derivati 2-(purin-9-il)-tetrahidrofuran-3,4-diola YU29099A (sh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9626846.1A GB9626846D0 (en) 1996-12-24 1996-12-24 Chemical compounds
GBGB9626852.9A GB9626852D0 (en) 1996-12-24 1996-12-24 Chemical compounds
GBGB9626845.3A GB9626845D0 (en) 1996-12-24 1996-12-24 Chemical compounds
GBGB9720536.3A GB9720536D0 (en) 1997-09-27 1997-09-27 Chemical compounds
GBGB9722730.0A GB9722730D0 (en) 1997-10-29 1997-10-29 Chemical compounds

Publications (1)

Publication Number Publication Date
YU29099A true YU29099A (sh) 2002-06-19

Family

ID=27517393

Family Applications (1)

Application Number Title Priority Date Filing Date
YU29099A YU29099A (sh) 1996-12-24 1997-12-22 Derivati 2-(purin-9-il)-tetrahidrofuran-3,4-diola

Country Status (36)

Country Link
US (2) US6426337B1 (sh)
EP (1) EP0948509B1 (sh)
JP (1) JP4156035B2 (sh)
KR (1) KR20000069682A (sh)
CN (1) CN1246124A (sh)
AP (1) AP1105A (sh)
AR (1) AR011044A1 (sh)
AT (1) ATE226212T1 (sh)
AU (1) AU733684B2 (sh)
BG (1) BG63310B1 (sh)
BR (1) BR9714082A (sh)
CA (1) CA2275271A1 (sh)
CO (1) CO4940488A1 (sh)
CZ (1) CZ230999A3 (sh)
DE (1) DE69716468T2 (sh)
DK (1) DK0948509T3 (sh)
EA (1) EA001714B1 (sh)
EE (1) EE04019B1 (sh)
ES (1) ES2186015T3 (sh)
GE (1) GEP20022656B (sh)
HU (1) HUP0000673A3 (sh)
ID (1) ID22271A (sh)
IL (1) IL130547A0 (sh)
IS (1) IS5089A (sh)
NO (1) NO312840B1 (sh)
NZ (1) NZ336332A (sh)
OA (1) OA11071A (sh)
PE (1) PE27499A1 (sh)
PL (1) PL334218A1 (sh)
PT (1) PT948509E (sh)
SI (1) SI0948509T1 (sh)
SK (1) SK86599A3 (sh)
TR (1) TR199901905T2 (sh)
TW (1) TW528755B (sh)
WO (1) WO1998028319A1 (sh)
YU (1) YU29099A (sh)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PE20000270A1 (es) 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6495528B1 (en) * 1998-06-23 2002-12-17 Smithkline Beecham Corporation 2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9930082D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0104555D0 (en) * 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
AU2002238748A1 (en) * 2001-03-12 2002-09-24 Glaxo Group Limited Pharmaceutical aerosol formulation
JP2002338593A (ja) * 2001-05-22 2002-11-27 Ajinomoto Co Inc β−Ｄ−リボフラノース誘導体又はその光学異性体の製造方法
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
US7932260B2 (en) 2004-05-13 2011-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
DE602005020286D1 (de) * 2004-05-26 2010-05-12 Inotek Pharmaceuticals Corp Purinderivate als adenosin a 1 rezeptoragonisten und anwendungsverfahren dafür
AU2005286946B2 (en) * 2004-09-20 2012-03-15 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP2532678A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0523845D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel salts
WO2007064795A2 (en) * 2005-11-30 2007-06-07 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA2975473C (en) 2008-11-13 2021-01-19 Gilead Calistoga Llc Therapies for hematologic malignancies
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
ES2548253T3 (es) * 2009-04-20 2015-10-15 Gilead Calistoga Llc Métodos para el tratamiento de tumores sólidos
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
JP2013513562A (ja) * 2009-12-09 2013-04-22 グラクソ グループ リミテッド 新規の医療用使用
JP2013516495A (ja) 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CN103732611B (zh) 2011-01-10 2016-06-01 伊沃恩有限公司 β-肾上腺素能反向激动剂用于戒烟的用途
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
WO2013134288A1 (en) 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2014047447A2 (en) * 2012-09-21 2014-03-27 Midwestern University Fto modulating compounds and methods of use
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CN105188714A (zh) 2013-03-15 2015-12-23 伊诺泰克制药公司 眼用配制品
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
JP2017502021A (ja) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤のためのプロセス方法
EP3154960A1 (en) 2014-06-13 2017-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
RU2695230C2 (ru) 2014-07-31 2019-07-22 Новартис Аг Сочетанная терапия
JP7125144B2 (ja) 2016-09-09 2022-08-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法
CN112888696B (zh) 2018-06-21 2024-04-16 德琪医疗有限公司 外核苷酸酶抑制剂及其使用方法
KR20220024629A (ko) * 2019-06-20 2022-03-03 칼리테라 바이오사이언시즈, 인코포레이티드 엑토뉴클레오티다제 억제제 및 이의 사용 방법
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE768925A (fr) 1970-06-30 1971-11-03 Takeda Chemical Industries Ltd Derives d'adenosine et procede de preparation
DE2034785A1 (de) 1970-07-14 1972-01-20 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Adenosin 5 carbonsäurederivate
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE789773A (fr) 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
US3864483A (en) 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1082695A (en) 1972-04-10 1980-07-29 Francis E. Fischer Process for preparing adenosine-5'-carboxamides
US3966917A (en) 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
DE2621470A1 (de) * 1976-05-14 1977-12-01 Pharma Waldhof Gmbh & Co Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung
US4167565A (en) 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
CA1239397A (en) 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US4496643A (en) 1984-03-23 1985-01-29 Eastman Kodak Company Two-component dry electrostatic developer composition containing onium charge control agent
EP0305643B1 (en) 1984-04-18 1994-01-05 Whitby Research Incorporated N-6 thienyl substituted adenosine derivatives as cardiac vasodilators
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4663313A (en) 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US4767747A (en) 1986-08-28 1988-08-30 Warner-Lambert Company Method for treating congestive heart failure with N6 -acenaphthyl adenosine
AU8274187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
AU8276187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
NL8702926A (nl) 1986-12-15 1988-07-01 Sandoz Ag Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
FI880405A (fi) 1987-02-04 1988-08-05 Ciba Geigy Ag Adenosin-5'-karboxamidderivat.
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4962194A (en) 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
LU87181A1 (fr) 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
JPH0725785B2 (ja) 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
CA2028002A1 (en) 1989-10-19 1991-04-20 Daniel P. Becker Method of treating gastrointestinal motility disorders
US5055569A (en) 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
DK0550631T3 (da) 1990-09-25 1997-01-20 Rhone Poulenc Rorer Int Forbindelser med blodtrykssænkende virkning og virkning mod iskæmi
FR2685918B1 (fr) 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687678B1 (fr) 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
AU4772493A (en) 1992-07-15 1994-02-14 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Sulfo-derivatives of adenosine
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
WO1994018215A1 (en) 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
AU7331094A (en) 1993-07-13 1995-02-13 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor agonists
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995018817A1 (fr) 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
GB9414193D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
ATE226212T1 (de) 2002-11-15
US6528494B2 (en) 2003-03-04
EA199900494A1 (ru) 2000-02-28
JP4156035B2 (ja) 2008-09-24
WO1998028319A1 (en) 1998-07-02
PE27499A1 (es) 1999-03-30
EE04019B1 (et) 2003-04-15
ES2186015T3 (es) 2003-05-01
DE69716468D1 (de) 2002-11-21
AU733684B2 (en) 2001-05-24
NZ336332A (en) 2000-12-22
HUP0000673A2 (hu) 2001-06-28
EP0948509B1 (en) 2002-10-16
CA2275271A1 (en) 1998-07-02
EE9900312A (et) 2000-02-15
US20020086850A1 (en) 2002-07-04
SI0948509T1 (en) 2003-06-30
KR20000069682A (ko) 2000-11-25
DK0948509T3 (da) 2003-02-24
SK86599A3 (en) 2000-05-16
CZ230999A3 (cs) 1999-12-15
JP2001506668A (ja) 2001-05-22
TR199901905T2 (xx) 1999-10-21
CN1246124A (zh) 2000-03-01
TW528755B (en) 2003-04-21
AR011044A1 (es) 2000-08-02
DE69716468T2 (de) 2003-05-28
PT948509E (pt) 2003-03-31
BR9714082A (pt) 2000-05-09
BG63310B1 (bg) 2001-09-28
NO312840B1 (no) 2002-07-08
EA001714B1 (ru) 2001-08-27
EP0948509A1 (en) 1999-10-13
NO993114D0 (no) 1999-06-23
OA11071A (en) 2002-11-18
AP9901572A0 (en) 1999-06-30
IL130547A0 (en) 2000-06-01
AU5762298A (en) 1998-07-17
AP1105A (en) 2002-09-04
PL334218A1 (en) 2000-02-14
NO993114L (no) 1999-08-23
US6426337B1 (en) 2002-07-30
CO4940488A1 (es) 2000-07-24
HUP0000673A3 (en) 2003-01-28
ID22271A (id) 1999-09-23
IS5089A (is) 1999-06-22
BG103518A (en) 2000-01-31
GEP20022656B (en) 2002-03-25

Similar Documents

Publication Publication Date Title
YU29099A (sh) Derivati 2-(purin-9-il)-tetrahidrofuran-3,4-diola
AP2000001875A0 (en) 2-(Purin-9-yl)-tetrahydrofuran -3,4-diol derivatives.
AP2000001881A0 (en) 2-(Purine-9-YL)-tetrahydrofuran-3,4 4-diol derivatives.
AP2000002016A0 (en) 2-(Purin-9-yl) Tetrahydrofuran-3,4-diol derivatives.
AU4613999A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AP2000002013A0 (en) 2-(Purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives.
CY1107391T1 (el) Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
IL114003A (en) 1,4,6-Trisubstituted 1H-pyrrolo[2,3-b]pyridine and 1-H-pyrazolo[3,4-b] pyridine derivatives and pharmaceutical compositions containing them and some intermediates for their preparation
TR200101709T2 (tr) İltihabik hastalıkların tedavisinde yararlı olan bileşikler
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
EP0305117A3 (en) 2',3'-dideoxy-3'-fluorothymidine and related compounds for the treatment of adenovirus infections
ES8604223A1 (es) Un procedimiento para preparar derivados de purina
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
BG101126A (en) The use of muramylpeptide compounds
MX9800049A (es) Antraquinonas mono- y disulfo-substituidas y su uso para el tratamiento de trastornos de la matriz del hueso.
NO991734L (no) Pyrazolinoner for behandling av potensforstyrrelser
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
DE3371515D1 (en) Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
EP0276805A3 (en) Substituted 3-phenyl-7h-thiazoloû3,2-b¨û1,2,4¨triazin-7-ones, processes for their preparation, medicaments containing them and their use as well as some of the intermediates obtained during the preparation of said compounds
ES8200886A1 (es) Procedimiento para la preparacion de derivados del amino-1 propanol-2
ES2106858T3 (es) Nuevos derivados de la citarabina, su procedimiento de preparacion y su uso contra enfermedades cancerosas.